Many cancer therapies, in addition to producing numerous side effects, fail to achieve complete tumour remission, partly due to the presence of cancer stem cells, which are difficult to eradicate.
Men with metastatic castration-resistant prostate cancer had a slight but significant improvement in progression-free survival with a TKI plus immunotherapy vs hormonal therapy.
Adding higher dose radiation led to long-term ADT led to better progression-free, cancer-specific, and overall survival vs standard-dose radiation in men with high-risk prostate cancer.